Impact of adjuvant anti-PD-1 immunotherapy on ovarian function in female patients with resectable melanoma: A prospective observational study
This prospective evaluation of ovarian function during and after adjuvant anti-PD-1 therapy in melanoma found no evidence of treatment-related ovarian insufficiency, including in patients with endocrine toxicities. These findings are important for counseling young patients receiving adjuvant therapy who may wish to conceive in the future.
Authors
- Eva Ellebæk (ORCID: https://orcid.org/0000-0001-6748-9232)
- Christina H. Bruvik Ruhlmann (ORCID: https://orcid.org/0000-0002-3728-273X)
- Lotte Berdiin Colmorn (ORCID: https://orcid.org/0000-0001-7570-2822)
- Troels Holz Borch (ORCID: https://orcid.org/0000-0002-4402-9281)
- Stine Gry Kristensen (ORCID: https://orcid.org/0000-0003-1194-8393)
- Jens Fedder (ORCID: https://orcid.org/0000-0001-5383-5501)
- Sidsel Pedersen
- Marco Donia
- Kirsten T. Macklon
- Inge Marie Svane
Institutions
- Odense University Hospital (DK)
- Herlev Hospital (DK)
- Copenhagen University Hospital (DK)
- Rigshospitalet (DK)
Publication Details
- Journal
- European Journal of Cancer
- Published
- 2026-02-17
- DOI
- https://doi.org/10.1016/j.ejca.2026.116584
- Primary Topic
- Immunotherapy and Immune Responses
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- Bristol-Myers Squibb
- Sanofi
- Helsinn
- Les Laboratories Pierre Fabre
- Novo Nordisk
- Astellas Pharma
- Cilag